Introduction
Suicide gene therapy has emerged as a potentially useful strategy for treatment of human malignancies. 1, 2 In this approach, the suicide gene encodes an enzyme (ie herpes simplex thymidine kinase (HSVtk) or cytosine deaminase) that is capable of converting a systemically delivered pro-drug (ie ganciclovir, 5-fluorocytosine) into a toxic metabolite that induces cell death. [3] [4] [5] [6] [7] A variety of vectors has been used to deliver suicide genes; however, the use of recombinant adenoviruses has probably stimulated the most research interest in the past decade. This is due to the ability of adenoviruses to infect a wide variety of dividing and non-dividing cells, their large packaging capacity (approximately 7.5 kb), and their ability to be propagated to produce high titers for use in clinical trials. 8, 9 Accordingly, adenoviral vectors encoding HSVtk (Ad.HSVtk) in combination with GCV have been used in several pre-clinical and clinical suicide gene studies directed against a variety of cancers including brain tumors, 10 head and neck tumors, 11 melanoma, 12,13 ovarian cancer, [14] [15] [16] and malignant mesothelioma. [17] [18] [19] [20] [21] Many of these animal studies have shown some therapeutic effects; however, one of the major shortcomings of adenoviral gene therapy has been the relatively low efficiency of recombinant gene transfer to target tumor tissues in vivo, thus, significantly limiting treatment efficacy. This occurs despite the presence of a 'bystander effect' where transfection of only a small percentage of malignant tumor cells is sufficient to achieve near complete tumor eradication in some animal studies. [22] [23] [24] [25] [26] The ability to increase the number of cells infected by in vivo administration of adenoviral vectors would therefore be a major advance in cancer gene therapy.
The underlying mechanisms that control initial interactions between adenoviruses and target cells are still unclear. Although, adenoviral receptors 27, 28 and accessory cell surface molecules such as integrins 29, 30 are important, some recent studies have suggested that adenoviral gene transfer efficiency may also be influenced by electrostatic repulsion between the negatively charged cell surface and the net negatively charged Ad. particles. [31] [32] [33] [34] In one study, 35 the removal of negatively charged sialic acid residues on cultured polarized epithelial cells was shown to significantly improve the efficiency of adenovirus-mediated gene transfer. The same investigators also demonstrated that gene transfer could be augmented by addition of polycations such as polybrene, poly-l-lysine, DEAE-dextran and protamine. Interestingly, the polyanion, heparin, did not significantly alter gene transfer efficiency, but completely abrogated the effects of polycations. 33 Furthermore, in in vivo studies, polycations were able to facilitate the epithelial cell uptake of adenoviral particles. 34, 36 Based on these data, we hypothesized that the use of polycations, perhaps via neutralization of membrane charges or bridging of Ad particles and tumor cell surfaces, would result in enhanced gene transfer and improved clinical efficacy in the setting of suicide gene therapy for intracavitary tumors. We focused on the use of the polycation, protamine sulfate, since this compound was effective in the previously mentioned studies and is a well established and safe drug in the human clinical setting where it is used to reverse the effects of heparin after cardiopulmonary bypass. To test this hypothesis, we first studied the effect of protamine on different tumor cell lines in vitro and correlated its effects with expression of the adenoviral high affinity binding site, coxsackievirus and adenovirus receptor (CAR), on cell surfaces. We next studied the effect of protamine in augmenting gene transfer to tumor cells in vivo. Finally, we tested the ability of protamine to increase the anti-tumor effects of the Ad.RSVtk/GCV system in two animal models of intracavitary cancers.
Results
Effect of protamine in vitro on efficiency of adenovirusmediated gene transfer In order to study the ability of protamine sulfate to enhance adenovirus-mediated gene transfer, we used a marker gene, namely, PECAM-1 (platelet-endothelial cell adhesion molecule-1), contained in an adenoviral (Ad) expression vector. PECAM-1 is a vascular cell adhesion molecule not normally expressed on the cell surface of any tumors used in our study. This molecule can be easily detected and quantified on cell surfaces by FACS analysis.
In order to optimize the dose of protamine used, we first examined two cell lines that were quite resistant to adenoviral infection, the rat mesothelioma cell line, II-45, and a ras-transformed murine fibroblast cell line (EJ-62). Using the Ad.PECAM-1 system as described above, the effect of protamine on cell infectability of adenovirus was examined in the FACS analysis as shown in Figure 1 . The measured mean fluorescence intensity (MFI), which is proportional to the number of PECAM-1 molecules per cell, peaked at a protamine concentration of 5 g/ml protamine (Figure 1a) . At doses higher than 5 g/ml protamine, cell infectability diminished. This optimal dose is similar to that described in the literature. 33 Figure 1b demonstrates Ad infectability of the II-45 cell line in the presence and absence of 5 g/ml protamine. The dose of virus was plotted against the percentage of cells infected as determined by FACS. Infection at 100 MOI in the presence of protamine resulted in an infection rate of approximately 90%, whereas in the absence of protamine this degree of infection could only be obtained at 1000 MOI. Similarly, Figure 1c shows that Ͼ87% of EJ-62 cells were infected at 100 MOI + protamine; however, in the absence of protamine only 68% cells could be infected at 1000 MOI.
Using the same Ad.PECAM-1 system, we next tested the infectability of eight cell lines: REN; I-45; H2052 (human mesotheliomas); II-45 (rat mesothelioma); A549 (human non-small cell lung carcinoma); H322 (human bronchioloalveolar carcinoma); HASMC (human airway smooth muscle cells); and EJ-62 (3T3 H-RAS transformed mouse fibroblasts). We infected these different cell lines at subconfluence in the presence and in the absence of 5 g/ml protamine sulfate.
As shown in Table 1 , protamine increased the infectability of our adenoviral vector as indicated by the upregulated expression of the PECAM-1 transgene at equivalent MOIs in the EJ-62, H2052, II-45 and HASMC cell lines by 22-, 11-, nine-and 4.5-fold, respectively. In A549, H-322 and I-45, the effects were smaller with increases of 1.9-, 1.3-and 1.2-fold, respectively. In the highly infectable REN cells, protamine had a deleterious effect on gene transfer, decreasing infectability two-fold.
Relationship of protamine effects to CAR expression
To explore the relationship between protamine effects and the expression of the high affinity adenoviral binding site, hCAR (human coxsackievirus and adenovirus receptor), expression levels of CAR were directly measured on the cell surface of the eight cell lines tested via FACS analysis using a well described murine monoclonal Ab (Rmcb) to hCAR. 37 Although not strictly quantitative, the mean fluorescent intensity (MFI) as determined by FACS is proportional to the number of hCAR molecules per cell. For purposes of comparison in multiple experiments, expression of hCAR (as measured by MFI) was normalized for each cell line by comparison to the well characterized, highly expressing HeLa cell line (ave MFI = 8.1). 37, 38 Thus, expression of hCAR on the surface of HeLa cells was standardized to 100% in each experiment. As shown in Table 1 , the cell lines with high surface expression levels of hCAR, such as REN, A549, H322 and I-45 cells (and high susceptibility to Ad infection), were the least affected by the addition of protamine. In contrast, addition of protamine to cell lines with low levels of hCAR expression such as HASMC and H2052 had much larger effects. Although we were not able to measure CAR expression directly in the non-human cell lines since the antibody did not cross react with rat or murine cells, 38 the EJ-62 and II-45 cells (also highly resistant to adenoviral infection) were much more easily transfected in the presence of protamine. Thus, our data support the hypothesis that the surface expression level of hCAR on the cell lines tested was inversely proportional to the effect of 5 g/ml protamine as measured by the fold decrease in MOI 50 (MOI needed to obtain 50% cells infected). 
-FC and GCV dose-response among uninfected cells (control) and cells infected with varying MOIs with and without protamine is shown. The cytotoxicity induced by either 5-FC or GCV after infection with Ad in the presence of protamine was substantially increased at reduced MOI for both cell lines tested. Error bars are too small to be seen.
cytotoxicity at 100 MOI in the presence of protamine compared with its absence.
To confirm that these results were not specific to Ad.CMVcd, we similarly evaluated the cytotoxicity induced by the tk/GCV system on the same rat mesothelioma cell line (II-45) and a murine cell line, EJ-62. Cells were infected using an Ad vector containing the HSVtk suicide gene (Ad.RSVtk) followed by 4 days of GCV exposure at varying concentrations. Cytopathic effect was again evaluated by MTS assay as shown in Figure 2b and c. In the presence of protamine, the observed cytotoxicity of II-45 infected cells exposed to GCV increased five-fold ( Figure 2b ). We obtained the same cytotoxicity (approximately 40% cell survival at 20 m GCV) at 250 MOI when compared with 50 MOI in the presence of protamine. Ad.RSVtk-infected EJ-62 cells were rendered 10-fold more sensitive to GCV when infections were performed in the presence of 5 g/ml of protamine as shown in Figure 2c . Similar cytotoxicity (approximately 20% cell survival at 20 m GCV) was obtained at 100 MOI versus 10 MOI in the presence of 5 g/ml protamine.
Effect of protamine on ganciclovir uptake in vitro To determine if protamine had any affect on the entry of GCV in vitro, rat mesothelioma cells (II-45) were incubated with incremental doses of protamine (0, 0.5, 5, 50, 500 g/ml) followed by 48 h of GCV. Intracellular GCV was measured via a method combining high performance liquid chromatography (HPLC) with mass spectroscopy. 39 We found no measurable improvement in GCV uptake when II-45 cells were incubated with 5 g/ml protamine (GCV = 0.007 ± 0.001 pg per cell) as compared with II-45 cells exposed to GCV in the absence of protamine (GCV = 0.008 ± 0.0012 pg per cell). A similar lack of change in intracellular GCV levels was observed at protamine concentrations of 0.5, 5 and 50 g/ml. Protamine at 500 g/ml was found to be toxic to II-45 cells in vitro.
Protamine improves surface gene transfer in vivo
To evaluate the effects of protamine on the efficiency of gene transfer in vivo, we administered an Ad expression vector containing a reporter gene, LacZ. Ad.CMVlacZ was administered i.p. in BALB/c mice bearing established intraperitoneal EJ-62 tumors. When tumors were approximately 4 mm size, animals received an i.p. injection (1 ml) of saline or of protamine at varying concentrations at both 2 h and at 5 min before i.p. administration of 2 × 10 9 p.f.u. of Ad.CMVlacZ. Three animals in each group per condition were killed the following day and carefully examined for the presence of gross tumor. Tumors were then removed and embedded in OCT. The blocks were sectioned (approximately 2 mm thick), fixed on glass slides and stained for LacZ expression with Xgal. Representative sections are depicted in Figure 3 . Under control conditions, intraperitoneal delivery of Ad.lacZ resulted in clearly detectable, but patchy X-gal staining on the surface of the tumors (Figure 3a) . Pretreatment with protamine at doses of 5 g/ml (Figure 3b ) and 50 g/ml (Figure 3c ) clearly increased gene transfer to the tumor surface, whereas no increase in surface staining was seen at the highest dose of protamine delivered, 500 g/ml (Figure 3d) . In pilot studies, no improvement in surface transfection was seen when protamine was complexed directly with Ad.lacZ before i.p. administration, regardless of protamine dose. Only pretreatment with protamine yielded consistent results as described above.
The efficiency of transfection (percentage of tumor surface showing blue staining), quantified by image analysis, is shown in Figure 4 . When infection was performed in the absence of protamine only 12% of the tumor surface was stained. This level of transfection (10% of surface cells) was also noted in the 500 g/ml group. The amount of surface staining was significantly increased to 30% and 50% in the presence of protamine at concen- trations of 5 and 50 g/ml (P = 0.0018 and Ͻ0.0001 when compared with controls, respectively).
Treatment efficacy observed with protamine use in vivo
To determine if the increased levels of surface transgene expression after protamine would translate into improved anti-tumor response or survival, two animal tumor models were studied.
Mice bearing macroscopic intraperitoneal EJ-62 tumors (n = 9 per group) were treated i.p. with either saline alone (control) or 6.0 × 10 9 p.f.u. Ad.RSVtk in the presence and absence of 50 g/ml of protamine (administered as pretreatment). This protamine dose was chosen as the concentration at which Ad-mediated gene transfer appeared most efficient in previous experiments as shown in Figure 4 . Twenty-four hours after i.p. administration of recombinant adenovirus with or without protamine, the mice received daily i.p. injections of GCV for a duration of 7 days and were followed for survival. An additional group (n = 9) was added to evaluate any potential benefit of virus alone (6.0 × 10 9 p.f.u. Ad.RSVtk) in the absence of both GCV and protamine. Median survival of control animals and animals receiving virus alone were identical in both immunocompetent ( Figure  5a To document if protamine was able to potentiate an adenovirus-mediated anti-tumor effect in a completely different animal model, tumor burden was assessed in an intrapleural mesothelioma model in Fischer rats. 20 Four days after intrapleural inoculation of 1 × 10 6 II-45 cells, groups (n = 10 per group) of rats were treated intrapleurally with saline alone, 2.0 × 10 8 p.f.u. Ad.RSVtk, or 2.0 × 10 8 p.f.u. Ad.RSVtk + 50 g/ml protamine. To evaluate the protamine/Ad vector response on tumor mass more easily, we used a relatively subtherapeutic dose (2.0 × 10 8 p.f.u.) of the Ad.RSVtk vector, since increasing the viral dose by an additional log reproducibly eradicates almost all tumor. One day following virus administration, all animals received intraperitoneal GCV for 7 days duration. All animals were killed 18 days after initial tumor inoculation and carefully examined for the presence of gross tumor. Tumors were excised and weighed to assess extent of tumor burden. All 30 animals had some tumor on the parietal pleural surface but the control group had a significantly larger tumor burden (3.66 ± 0.17 g) compared with treatment groups (virus = 1.79 ± 0.2 g; virus + protamine = 1.62 ± 0.15 g) (P Ͻ 0.0001). The experiment was repeated three times using identical methodology with reproducible results. All experiments were normalized to internal control weights (g) and combined as shown in Figure 6 . No significant improvement in anti-tumor effect (P = 0.5658) could be demonstrated between treated groups receiving recombinant Ad.tk in the presence of 50 g/ml protamine versus no protamine.
Discussion
The process of adenoviral entry into cells entails at least two different receptors, one mediating attachment and the other mediating internalization. 29 Adenovirus attachment to cells is clearly mediated by fibers projecting from the adenoviral capsid. Bergelson et al 40 recently described and cloned the first adenoviral receptor protein derived from HeLa cell lysates, coxsackievirus and adenovirus receptor (CAR), that was found to attach to the viral capsid fiber protein. CAR-transfected hamster cells bound adenovirus in a fiber-dependent fashion and showed a 100-fold increase in susceptibility to virus-mediated gene transfer. 40 Likewise, CAR-transfected murine lymphocytes (normally CAR-deficient and resistant to Ad infection) were rendered more susceptible to adenoviral transduction via the same fiber-dependent pathway. 41 Although adenovirus internalization (as opposed to binding) is mediated by the interaction between adenovirus penton base and cell surface receptors, namely, 29, 30 expression of ␣ v integrin alone is not sufficient to achieve an efficient gene transfer. The expression of both receptors appears to be necessary for efficient adenoviral gene transfer. 31 In addition to these two receptors, the interaction of charges on the surface of the cell membrane appears to play a significant role in cell binding and entry of adenovirus. Arcasoy et al 35 have shown that Ad-mediated transducibility of epithelial cells is increased when the negatively charged sialic acid residue are removed from the epithelial cell membranes. The fiber receptor mediated pathway is not involved in the increased gene transfer observed with the use of polycations. 34 However, the mechanism by which polycations increase gene transfer is not well understood. One mechanism of cellular resistance to adenoviral infection appears to be mediated by lack of the fiber-dependent pathway. We have confirmed along with others 41, 42 that cell lines which express a paucity of the high affinity Ad binding site, CAR, demonstrate poor susceptibility to adenoviral infection. This barrier to adenoviral binding/entry appears to be overcome in the presence of polycations like protamine.
Figure 6 Effect of protamine on Ad-mediated suicide gene therapy in an intrapleural mesothelioma model in Fischer rats. Tumor burden in a syngeneic intrapleural mesothelioma (II-45) model in 344 Fischer rats. Tumor was established on day 0 via an intrapleural injection of 1
Previous studies have shown that polycations potentiate Ad-mediated gene transfer both in vitro and in vivo to respiratory epithelial cells. 33, 34, 36 We hypothesized that one of the polycations, protamine, could be applied to cancer gene therapy to improve transfection efficiency of Ad-delivered suicide genes in vitro and in vivo. Although many polycations (ie DEAE-dextran, poly-l-lysine, polybrene, and protamine) have been evaluated in animal models, our laboratory focused on protamine sulfate due to its proven safety record in humans. Protamine has been safely administered to humans since the 1950s (FDA approval 1951, UpJohn Pharmaceuticals, Kalamazoo, MI, USA) and therefore could provide an effective and inexpensive adjunct to improve adenoviral gene therapy.
Our results indicate that protamine augments Admediated gene transfer efficiency in a wide variety of cancer cell lines in vitro. Interestingly, the most difficult cells to infect showed the greatest improvement after treatment with protamine. Furthermore, our data suggest that the degree of protamine augmentation is inversely proportional to expression of the cell surface molecule, CAR. The mechanism for this augmentation is not known for certain; however, polycationic molecules appear to increase adenoviral binding via a fiber-independent pathway. Evidence to suggest such a pathway is corroborated by Fasbender et al, 34 who demonstrated that polycations could enhance susceptibility to adenoviral gene transfer even in the presence of competing fiber protein. Protamine may augment adenoviral adsorption to some negatively charged moieties present on the cell surface. Wickham et al 42 suggested a similar mechanism where Admediated gene delivery was dramatically enhanced (approximately 70-fold) to CAR insufficient cells (ie human umbilical vein endothelial cells and human fibroblasts) with a modified Ad vector containing a positively charged moiety attached to the end of the fiber protein. 42 This effect was completely abrogated by the addition of heparinase or soluble heparin, confirming viral attachment via a negatively charged or heparancontaining moiety. We believe that this mechanism parallels our observations of enhanced adenoviral transfection in the milieu of a positively charged molecule like protamine.
Protamine also augmented Ad-induced cytotoxicity when administered with viral vectors containing suicide genes (ie cytosine deaminase or HSVtk) in the presence of the appropriate prodrug. This phenomenon is likely due to increased viral uptake as protamine did not alter GCV concentration within the cells. Augmentation did not appear to be cell line specific or transgene specific. Consistent with these observations, protamine clearly increased the efficiency of surface LacZ gene transfer after being co-administered with virus into the peritoneal cavity of mice, as demonstrated by increased surface transfection of established intraperitoneal tumor ( Figure 3 ) treated with i.p. Ad.CMVlacZ. For reasons that are currently unclear, we found that incubation of a mixture of adenovirus with protamine was less effective at improving gene transfer efficiency compared with pretreatment with protamine injection followed by adenoviral therapy (data not shown). This phenomenon was not observed in any of our in vitro studies where vector and protamine could be added simultaneously with good effect. Arcasoy et al 35 reported similar observations when using various polycations in vitro and in vivo. In contrast, Kaplan et al 36 demonstrated that ex vivo preparations of Ad/polycation complexes were effective in augmenting gene transfer of LacZ in mouse lung in vivo. Kaplan did make the observation that, while Ad vector and poly-l-lysine needed to be instilled simultaneously to produce increased levels of expression in murine lung, DEAE-dextran could be administered as a separate instillation followed by Ad vector some time later. These findings suggest that enhanced transfection by Ad/polycation complexes may vary for different polycations.
Given these in vitro and in vivo observations, we hypothesized that protamine, in conjunction with recombinant adenovirus, would improve the therapeutic index of Adbased cancer suicide gene therapy. Somewhat surprisingly, we observed no improvement in anti-tumor response or prolonged survival in two independent intracavitary animal tumor models. The reason for this lack of augmented efficacy is not known; however, one explanation is that protamine's enhancement of Ad-based cancer gene therapy in vivo appears to be a surface phenomenon only. We hypothesize that protamine only augmented surface transfection of transgene without increasing depth of adenoviral penetration into solid tumor, thus preventing any significant augmentation of clinical anti-tumor effect in the intracavitary models that we tested. It is doubtful that prodrug availability was limiting since the doses used in these studies have been used in the rat model with higher doses of virus and have led to almost complete tumor regressions. It is also possible that the full effect of protamine in vivo was impaired by the presence of intracavitary serum as reported by Fasbender et al 34 when using polycations in vitro. Augmentation of efficacy in other tumor models where direct injection of vector is performed (ie brain tumors) is possible and should be studied.
Despite the lack of improved efficacy in suicide gene therapy, the enhanced surface expression of transgene seen in vivo after protamine treatment might still be useful. In certain types of somatic gene therapy where infection of the mesothelium has been proposed, augmented gene expression would be advantageous. For example, infection of the peritoneal cavity with adenoviruses encoding proteins such as ␣ 1 -antitrypsin, factor VIII, factor IX, erythropoietin, granulocyte colony-stimulating factor, granulocyte-colony stimulating factor, or growth hormone could have some therapeutic efficacy. [43] [44] [45] [46] [47] [48] [49] Delivery of adenoviral vectors containing anti-inflammatory drugs to inhibit adhesion formation after surgery could be another application. In this setting, protamine could perhaps be used as an adjunct to increase transfection efficiency of an Ad vector containing the therapeutic gene product to a augment expression on the peritoneal mesothelium. Finally, the use of protamine might be advantageous in in vitro studies when using cells that are difficult to transfect with adenovirus. Addition of protamine could allow the use of much lower doses of virus to achieve the same or improved efficacy, and possibly reduce cellular toxicity. Significant cost savings could be realized implementing this strategy in human clinical trials where equivalent treatment efficacy could be obtained with reduced Ad dosages.
In summary, we have demonstrated that a wide range of cancer cells can be made more infectable to adenovirus by addition of the polycation protamine. We have also demonstrated that protamine can augment surface gene transfer in intracavitary tumors. Nonetheless, this increase in surface gene transfer did not result in augmented anti-tumor effects in mice or rats with intraperitoneal or intrapleural tumors treated with Ad. HSVtk/GCV. Thus, although protamine induces an enhancement of Ad-mediated gene transfer in vitro and in vivo, its use as an adjunct to intracavitary Ad-based cancer gene therapy in vivo appears to be limited.
Materials and methods

Cell lines
HeLa is a human cervical adenocarcinoma cell line obtained from the American Type Culture Collection (ATCC No. CCL-2). These cells were cultured and maintained in DMEM (Dulbecco's modified Eagle medium; Mediatech, Washington, DC, USA) supplemented with 10% fetal calf serum (FCS), 100 U/ml penicillin G, 100 g/ml streptomycin, and 2 mm glutamine. Primary human umbilical vein endothelial cells, HUVEC, were obtained from Clonetics (San Diego, CA, USA) and cultured in Media 199 supplemented with 15% FCS, 25 mg endothelial growth factor (EGF), 50 mg heparin sodium salt (Sigma, St Louis, MO, USA), and 2 mm glutamine. Primary human airway smooth muscle cells, HASMC, were provided as a gift from Dr Ray Panettieri Jr (University of Pennsylvania Medical Center, Philadelphia, PA, USA) and isolated fresh from transplant donor trachea. The cells were cultured in HAM-F12 nutrient media supplemented with 10% FCS, 10 ml (1 m NaOH), and 1.7 ml (1 m CaCl 2 ). REN is a human mesothelioma cell line isolated in our laboratory from a patient tumor specimen. 17 II-45 is a syngeneic Fischer rat malignant mesothelioma cell line that was previously established from experimentally induced mesothelioma in F344 rats exposed to asbestos. 50 I-45 and H2052 are human mesothelioma cell lines provided as a gift from Joe Testa PhD (Fox Chase Cancer Institute, Philadelphia, PA, USA). A-549, a non-small cell lung carcinoma and H-322, human bronchioloalveolar carcinoma cell line were obtained from the ATCC (Rockville, MD, USA). These cell lines were cultured and maintained in RPMI 40 (Roswell Park Medical Institute) media supplemented with 10% FCS, 100 U/ml penicillin G, 100 g/ml streptomycin, and 2 mm glutamine. EJ-62 is a BALB/c mouse fibroblast cell line transformed with the H-Ras oncogene derived from a human bladder carcinoma. It was obtained from ATCC and maintained in DMEM media with 10% FCS, 100 U/ml penicillin G, 100 g/ml streptomycin, and 2 mm glutamine.
Adenoviral vectors
The production of recombinant replication-deficient adenoviral vectors has been described in detail elsewhere. 17, 19, 51, 52 Briefly, the vectors were constructed from an adenovirus serotype 5 (Ad5) backbone lacking most of the viral sequence from the E 1 A and E 1 B regions and a portion of E 3 region. The suicide gene, herpes simplex type I thymidine kinase (HSVtk), was inserted via homologous recombination techniques into the E 1 region of this recombinant E 1 E 3 -deleted vector. The HSVtk minigene was placed under transcriptional control of a Rous sarcoma virus (RSV) promoter yielding Ad.RSVtk. The Ad.CMVcd virus was a gift from Dr Prem Seth (Medical Breast Cancer Center Section, National Cancer Institute, Bethesda, MD, USA). The E. coli-derived cytosine deaminase suicide gene, driven by a CMV promoter, was inserted by homologous recombination into the E 1 -deleted viral genome. 53 The PECAM-1 cDNA driven by a CMV promoter was also inserted by homologous recombination techniques as described previously to produce Ad.CMVPECAM-1. 26 The Ad.CMVlacZ virus used in our studies has been characterized previously. 54 All viral stocks were maintained and produced in 293 cells and titers were quantified by 293 plaque assay.
Adenoviral infection of cells
All cell lines were grown to 80-90% confluency in T 25 cell culture flasks. Stock solution of adenovirus in 5% glycerol was diluted to the appropriate concentration using serum-free medium for each cell line. Flasks were incubated at 37°C in 5% CO 2 for 2 h, after which the viral suspension was removed and replaced with fresh medium containing 10% FBS. For in vitro infections performed in the presence of protamine, adenovirus was diluted in serum-free media containing varying concentrations of protamine ranging from 0.5 g/ml to 500 g/ml. Most infections were performed with 5 g/ml of protamine sulfate, a concentration determined to be optimal in previous studies. 33 In vitro sensitivity assay To test the sensitivity of Ad.RSVtk and Ad.CMVcd to GCV or 5-fluorocytosine, respectively, subconfluent monolayers of tumor cells were infected at various MOI as described previously. 26 After a 24-h incubation period, infected cells were plated in 96-well plates in triplicate at a density of 500 cells per well in 100 l of media containing 10% FBS. Cells were then incubated for 5 additional days at 37°C with various concentrations of GCV (Hoffmann-La Roche, Nutley, NJ, USA) or 5-fluorocytosine (Sigma) diluted in media containing 10% FBS. Cell survival was assessed using a MTS colorimetric cell proliferation assay that measures the viable cell dehydrogenase activity 17 (CellTiter 96 Aqueous Non-radioactive MTS Cell Proliferation Assay; Promega Corporation, Madison, WI, USA). All values were compared with control cells that received GCV alone.
Analysis of adenovirus gene expression
Cells were infected with Ad.PECAM-1 in the presence or absence of 5 g/ml protamine at various MOI as described previously. One day after infection, cells were trypsinized and suspended in media containing 10% FBS. Cells were then incubated with 100 l of primary antibody (monoclonal murine anti-PECAM antibody (4G6)) at 4°C for 1 h followed by incubation with secondary antibody (FITC-conjugated goat anti-mouse IgG (Sigma)) for 30 min at 4°C. Cell surface expression of the PECAM molecule was analyzed by flow cytometry (FACScan; Becton Dickinson, San Jose, CA, USA). The analysis was repeated at least three times for each different cell line tested.
EJ-62 and II45 cells were infected with Ad.PECAM-1 in the presence of escalating doses of protamine (0, 0.5, 5, 50, 500 g/ml) to determine the optimal dose of protamine for in vitro transfections. EJ-62 cells were infected at 500 MOI while II-45 cells were infected at 100 MOI at each respective protamine dose. Infections were performed as described above. Cells were harvested 24 h after infection and prepared under conditions already described to measure PECAM expression on cell surfaces.
Detection of hCAR expression on cell surface of different tissues
The monolayers of various cell lines were trypsinized from T 25 flasks and suspended in media containing 10% FBS. Cells (10 6 ) were then incubated with a 1:500 dilution in 4% BSA in PBS of primary antibody (RmcB monoclonal ascites fluid) 37 for 1 h. The cells were washed twice with PBS and incubated with a 1:200 dilution of secondary antibody (FITC-conjugated goat anti-mouse IgG (Sigma)) for 30 min at 4°C. Cell surface expression was analyzed by flow cytometry. The epithelium-derived carcinoma cell line, HeLa, is known to express high levels of hCAR on the cell surface, and thus was used as a positive control for the assay. 38, 40 Mean fluorescent intensity for each cell line was measured and subsequently normalized to the expression of hCAR on HeLa cells to yield relative expression of hCAR.
Analysis of protamine's affect on ganciclovir in vitro
To determine if protamine affected the uptake of ganciclovir, monolayers of rat mesothelioma cells (II-45) were incubated with escalating concentrations of protamine (0.5, 5, 50, 500 g/ml) diluted in serum-free media. Flasks were incubated at 37°C in 5% CO 2 for 2 h (simulating conditions of Ad infection), after which the protamine suspension was removed and replaced with fresh RPMI containing 10% FBS and 20 m GCV. After a 48-h incubation with GCV, cells were trypsinized, counted, and centrifuged to obtain cell pellets stored at −80°C. Pelleted cells were thawed and reconstituted in 50 l dH 2 O mixed with 25 l of an internal standard containing 5 ng/l of acyclovir (Faulding Pharmaceuticals, Elizabeth, NJ, USA). The samples were vortexed for 2 min and methanol (200 l) was added in order to precipitate cellular proteins. Samples were vortexed again for 2 min followed by centrifugation at 16 000 g for 2 min. The supernatants were transferred and filtered through a 0.2 m Costar Spin-X HPLC micro-centrifuge filter (Costar, Cambridge, MA, USA). The filtrates were dried under nitrogen at room temperature. After drying, the residue was reconstituted by adding 250 l of water, vortexed and 70 l was injected on to a HPLC column. A method using reverse-phase liquid chromatography coupled with electrospray ionization and selected reaction monitoring mass spectroscopy has been developed for the quantitative analysis of total GCV in cells. 39 Measurements were normalized to the number of cells per sample to yield total GCV in pg per cell.
Animal studies
Female BALB/c mice (4-6 weeks old weighing approximately 25 g) were obtained from Taconic Laboratory (Germantown, NY, USA) and maintained in the animal facility at the Wistar Institute (Philadelphia, PA, USA). Female Fischer 344 rats (weighing 150 g) were obtained from Taconic and maintained in the animal facility at the John Morgan Building, University of Pennsylvania (Philadelphia, PA, USA). The Animal Use Committees of the Wistar Institute and University of Pennsylvania approved all protocols in compliance with the guide for the care and use of laboratory animals. EJ 62 mice model Intraperitoneal tumor was established by an i.p. injection of 1 × 10 4 EJ62 cells suspended in an injection volume of 1 ml serum-free DMEM media using a 26 gauge needle. Within 7 days, macroscopic tumor nodules were visible in the peritoneum. To determine if protamine was able to increase the viral gene transfer, mice in the treatment groups (n = 3) were injected on day 10 with 0.5 ml of protamine at three doses (5 g/ml, 50 g/ml, and 500 g/ml) approximately 2 h and again at 5 min before intraperitoneal administration of 2 × 10 9 p.f.u. of Ad.CMVlacZ. Preliminary studies revealed that simultaneous injection of protamine plus vector did not augment gene transfer regardless of protamine dose. The following day, all animals were killed and tumor was removed, embedded in OCT compound, and frozen in liquid nitrogen. Tumor sections were processed for X-gal staining as previously described. 54 The extent of transgene expression was expressed as the percentage of tumor surface staining positively for X-gal (indicated by blue surface staining) as determined by image analysis. A protamine dose of 50 g/ml proved to be the most efficacious in this study and was subsequently used in the ensuing survival study.
EJ62 survival study Intraperitoneal tumor was established in both an immunocompetent (BALB/c) and immunodeficient (SCID) mouse by i.p. injection of 1 × 10 4 EJ62 cells in 1 ml of serum-free DMEM media. On day 8, macroscopic tumor was identified on the bowel mesentery and retroperitoneum. Treatment animals (10 animals per group) then received an i.p. injection of Ad.RSVtk at a dose of 6.0 × 10 9 p.f.u. in 0.5 ml serum-free DMEM with and without pre-injection with protamine sulfate (Fujisawa, Deerfield, IL, USA) followed by 7 days of i.p. GCV at 50 mg/kg/day. Control animals received sham injections of serum-free DMEM media in lieu of GCV.
Protamine at 50 g/ml was administered i.p. in 1 ml serum-free DMEM media at two separate time points, both at 2 h and at 5 min before the administration of recombinant adenovirus. The second dose of protamine was prepared in an injection volume of 0.5 ml at 100 g/ml to accommodate for the viral injection volume of 0.5 ml. Animals were followed for survival and necropsied at time of death.
Fisher rat pleura mesothelioma model An animal mesothelioma model using II-45 cells was developed previously and characterized in our laboratory in immunocompetent Fischer 344 rats. 54 Briefly, Fischer 344 rats were anesthetized using intramuscular ketamine (90 mg/kg) and xylazine (10 mg/kg). Intra-thoracic tumor was established by administration of 1 × 10 6 II-45 cells suspended in 200 l of serum-free RPMI media into the left pleural cavity via a mini-thoracotomy technique with a 26 gauge needle. Within 4 days following tumor injection, multiple 2-4 mm macroscopic tumor nodules were visible at the level of the mediastinum and on the parietal and visceral pleural surfaces. To document if protamine was able to potentiate an adenovirusmediated anti-tumor effect, rats were injected on day 4 with either 50 g/ml protamine (250 l injection volume in RPMI) or serum-free RPMI alone 25 min before intrapleural injection of 2 × 10 8 p.f.u. (150 l injection volume) of Ad.RSVtk. This time point was chosen as a reasonable duration of time that the animal's thoracotomy incision could remain open in an effort to separate injections of protamine and virus. The following day (day 5) osmotic gradient pumps, which delivered 50 mg/kg/day GCV for 7 days, were surgically implanted into the peritoneal cavity of all rats. The control group included animals injected intrapleurally with tumor cells alone. Animals were killed on day 18 and necropsied. Tumors were dissected from normal tissue and weighed to assess tumor burden.
Statistical analysis
Differences in tumor weights in the animal experiments were determined with one-way analysis of variance (ANOVA). Post hoc comparisons of specific paired groups were performed using Bonferroni/Dunn analysis. Statistical significance was set at P Ͻ 0.05. Survival curves were analyzed with the Mantel-Cox log rank test. Results are expressed as the mean ± standard error (M ± s.e.).
